عنوان

New agents for the treatment of acute lymphoblastic leukemia /

شابک

1441984585

شابک

1441984593

شابک

9781441984586

شابک

9781441984593

شابک اشتباه

9781441984586

شماره

b430545

عنوان اصلي

New agents for the treatment of acute lymphoblastic leukemia /

نام عام مواد

[Book]

نام نخستين پديدآور

Vaskar Saha, Pamela Kearns, editors

نام خاص و کميت اثر

1 online resource (xviii, 338 pages)

متن يادداشت

Includes bibliographical references and index

متن يادداشت

New Agents for the Treatment of Acute Lymphoblastic Leukemia; Brief Overview; Acknowledgements; Contents; Contributors; Glossary; Chapter 1: The Need for New Agents; Chapter 2: Identifying Targets for New Therapies in Children with Acute Lymphoblastic Leukemia; Chapter 3: Preclinical Evaluation; Chapter 4: Design of Early-Phase Trials; Chapter 5: Strategies for Trial Design and Analyses; Chapter 6: An Overview on Animal Models of ALL; Chapter 7: Targeting Bcl-2 Family Proteins in Childhood Leukemia; Chapter 8: Targeting Leukemia Stem Cells and Stem Cell Pathways in ALL

متن يادداشت

Chapter 9: Nucleoside AnaloguesChapter 10: FLT3 Inhibitors as Therapeutic Agents in MLL Rearranged Acute Lymphoblastic Leukemia; Chapter 11: The Role of Tyrosine Kinase Inhibitors in the Treatment of ALL; Chapter 12: Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia; Chapter 13: Therapeutic Utility of Proteasome Inhibitors for Acute Leukemia; Chapter 14: Targeting Epigenetic Pathways in ALL; Chapter 15: Incorporating New Therapies into Frontline Protocols; Index

بدون عنوان

0

بدون عنوان

8

متن يادداشت

New Agents for the Treatment of Acute Lymphoblastic Leukaemia (ALL), examines the strategies for the use of new agents as well as possible targets of therapy in this disease. Though associated with high cure rates, relapsed disease has a poor outcome. Moreover, therapy is unduly prolonged and toxic. For over 4 decades, no new drugs have been available and now we have a surfeit. The challenge is to design trials to evaluate the potential efficacy of non-targeted therapy in a disease with good outcome. An increasing number of pathways, amenable to targeted therapy are also being identified. The heterogeneity of ALL suggests that targeted therapy at the moment will need to be tailored to the patient. How then can such drugs be evaluated within conventional clinical trials? These are the crossroads we have reached in acute lymphoblastic leukaemia and this book discusses and proposes some solutions to these issues

منبع سفارش / آدرس اشتراک

Springer

شماره انبار

978-1-4419-8458-6

عنوان

New agents for the treatment of acute lymphoblastic leukemia.

موضوع مستند نشده

Drugs-- Design

موضوع مستند نشده

Drugs-- Research

موضوع مستند نشده

Lymphoblastic leukemia-- Chemotherapy

موضوع مستند نشده

Adolescent

موضوع مستند نشده

Antineoplastic Agents-- therapeutic use

موضوع مستند نشده

Child

موضوع مستند نشده

Clinical Trials as Topic

موضوع مستند نشده

Precursor Cell Lymphoblastic Leukemia-Lymphoma-- drug therapy

موضوع مستند نشده

Treatment Outcome

شماره

ويراست

شماره رده

نشانه اثر

شماره رده

شماره رده

مستند نام اشخاص تاييد نشده

Kearns, Pamela

مستند نام اشخاص تاييد نشده

Saha, Vaskar

تاريخ عمليات

20170726082057.0

قواعد فهرست نويسي ( بخش توصيفي )

pn

نام الکترونيکي

نوع ماده

[Book]

تكميل شده

Y